Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Entero Therapeutics (ENTO)
NASDAQ:ENTO
RESEARCH TOOLSreports
Entero Therapeutics (ENTO) Stock Price & Analysis
1,209 Followers
ENTO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.92 - $22.20
Previous Close$1.04
Volume24.07K
Average Volume (3M)75.62K
Market Cap
$2.57M
Enterprise Value-$310.83K
Total Cash (Recent Filing)$3.71M
Total Debt (Recent Filing)$826.84K
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Aug 13, 2019EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-49.23
Shares Outstanding2,475,090
10 Day Avg. Volume40,311
30 Day Avg. Volume75,619
Standard Deviation0.26
R-Squared0.08
Alpha-0.14
Financial Highlights & Ratios
Price to Book (P/B)-1.06
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.52
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$36.00Price Target Upside3395.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Entero Therapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENTO FAQ
What was Entero Therapeutics’s price range in the past 12 months?
Entero Therapeutics lowest stock price was $0.92 and its highest was $22.20 in the past 12 months.
What is Entero Therapeutics’s market cap?
Currently, no data Available
When is Entero Therapeutics’s upcoming earnings report date?
Entero Therapeutics’s upcoming earnings report date is Aug 13, 2019 which is 1801 days ago.
How were Entero Therapeutics’s earnings last quarter?
Currently, no data Available
Is Entero Therapeutics overvalued?
According to Wall Street analysts Entero Therapeutics’s price is currently Undervalued.
Does Entero Therapeutics pay dividends?
Entero Therapeutics does not currently pay dividends.
What is Entero Therapeutics’s EPS estimate?
Entero Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Entero Therapeutics have?
Entero Therapeutics has 2,475,090 shares outstanding.
What happened to Entero Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Entero Therapeutics?
Currently, no hedge funds are holding shares in ENTO
---
Entero Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.00 (3395.15% Upside)
$36.00 (3395.15% Upside)
Blogger Sentiment
Bullish
ENTO Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $2.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.52%
12-Months-Change
Fundamentals
Return on Equity
-15.28%
Trailing 12-Months
Asset Growth
1546.81%
Trailing 12-Months
Company Description
Entero Therapeutics
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It focuses on MS1819-SD, and B-Lactamase program products. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY.
---
ENTO Stock 12 Month Forecast
Average Price Target
$36.00
▲(3395.15% Upside)
Technical Analysis
Arvinas Holding Company
―
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
BioMarin Pharmaceutical
―
Best Analysts Covering ENTO
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-64.28%
assigned a buy rating 2 months ago
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -64.28% per trade.
---